A Phase II, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

Trial Profile

A Phase II, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2018

At a glance

  • Drugs MABp1 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors XBiotech
  • Most Recent Events

    • 13 Sep 2018 Results published in the XBiotech Media Release
    • 13 Sep 2018 According to a XBiotech media release, announced that it has completed the first cohort of its open label pilot study in Atopic Dermatitis.In the first phase of the study, 9 patients received a low dose over a short course of treatment.Multiple secondary endpoints used to assess efficacy showed significant improvements.The study will now begin enrollment of 20 patients to receive 400mg weekly doses over an 8 week treatment period.
    • 29 Aug 2018 Planned number of patients changed from 20 to 29.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top